The molecular landscape of leukemia and lymphoma has expanded exponentially in the last two decades, giving rise to groundbreaking therapeutics and clinical research. However, the complexity and scope of biomarkers makes molecular analysis difficult for any single approach. Point mutations, gene fusions and other complex mutation types like FLT3 internal tandem duplications (IDTs) are particularly important to detect and characterize in hematological malignancies, yet traditional detection methods lack the ability to multiplex and provide nucleotide-level information. Targeted next generation sequencing is a promising medium to simultaneously interrogate multiple mutation types.
Archer FusionPlex® and VariantPlex™ assays are next-generation sequencing (NGS)-based assays powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect multiple mutation types and gene expression profiling in a single sample. In this webinar, Dr. Laura Griffin and Darius Fugere will discuss the different hematological disease states, their biology, driver mutations and current detection methods. They will also share data demonstrating how Archer Blood Cancer NGS Assays enable detection of all driver mutation types.
Laura Griffin earned her PhD in Microbiology from the University of Colorado Denver, Anschutz Medical Campus. Her research focused on cancer virology, dissecting virus-host interactions during Human Papillomavirus infection. Laura is passionate about cancer research as well as effective education and communication of scientific ideas. Laura joined the ArcherDX team as Scientific Editor in January, 2016.
Darius is a Colorado native who obtained his BA in integrated physiology and is now an MBA candidate at the University of Colorado, Boulder. He joined ArcherDx in early 2014 after pursuing several Boulder-based tech ventures. He is currently a product manager for custom and blood cancer-related NGS assays.
2477 55th Street, Suite 202
Boulder, CO 80301